Navigation Links
Final Data From the SEISMIC Trial Suggest Safety, Efficacy of Autologous Stem- Cell Therapy for Treating Congestive Heart Failure
Date:4/1/2008

ncluding digital imaging and standard quality of life measurement such as the six-minute walking test, New York Heart Association (NYHA) heart failure classification and Minnesota Living with Heart (MLHF) questionnaire. Final six-month results observed in the SEISMIC Trial include:

-- 84 percent of treated patients experienced improved or unchanged six-

minute walking test scores compared to 16 percent of the control group

- 69 percent of the control group's results worsened, versus only 16

percent of the treated group

-- 94 percent of treated patients experienced improved or unchanged NYHA

classification compared to 58 percent of the control group

- 42 percent of the control group's results worsened, versus only 6

percent of the treated group

Prof. Serruys also noted that reports of arrhythmia among the patients evaluated in SEISMIC, both in terms of total number of episodes as well as timing of episodes, were no different between the treatment and control arms in the study. This suggests that MyoCell is not associated with a higher prevalence of arrhythmias; rather, that arrhythmias are an expected occurrence for this subset of heart failure patients.

"These data support the need for a randomized, double-blind, placebo- controlled study involving the MyoCell technology," said Prof. Serruys. "We look forward to applying our learning from this trial to the larger, more comprehensive MARVEL(2) Trial currently underway in the U.S. and Europe." The MARVEL Trial, a randomized, double-blind, placebo-controlled, multi-center Phase II/III Trial involving 330 patients in North America and Europe, is the largest trial of its kind to date. Enrollment in the MARVEL Trial began in October 2007, targeting patients who fall into Class II or III heart failure. The MARVEL Trial will further study the safety and efficacy of the minimally invasive MyoCell autologous stem-cell th
'/>"/>

SOURCE Bioheart, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
2. Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting
3. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
4. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
5. TAXUS(R) Stent Demonstrates Similar Outcomes in Diabetic Patients Compared to Non-diabetics in Pooled Analysis of TAXUS IV and V Trials
6. Major Deficiencies in Design; Funding of Clinical Trials Affects Future of Scientific Innovation
7. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
8. CVBT Appoints Dr. Nabil Dib as Principal Investigator for Phase II Heart Trial
9. ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III)
10. Monogram Biosciences Provides Progenics Pharmaceuticals with HIV Assays for Use in Clinical Trials
11. CardioMind Launches First-in-Human Trial of Small Vessel, Drug-Eluting Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... VEGAS , Jan. 23, 2015 Cord Blood America, ... ) ("CBAI" or the "Company")  filed a Preliminary Proxy Statement, ... www.sec.gov ) today, and provides an update for shareholders detailing ... shares is requested. Dear Shareholders, As ...
(Date:1/23/2015)... BIRMINGHAM, Ala. , Jan. 23, 2015 Gem ... (STS) patients have been enrolled into the Company,s Phase ... efficacy and safety of Gem,s lead compound, GPX-150 (an ... for advanced or metastatic disease. Logo - ...
(Date:1/22/2015)... Colo. , Jan. 22, 2015  BiOptix is pleased ... as Vice President of Chemistry and Biochemistry. Scott joins ... Pharmaceuticals, AstraZeneca Pharmaceuticals, and Amgen throughout the course of ... development. "Scott is a nationally recognized thought ...
Breaking Medicine Technology:Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 3Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 4Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2BiOptix Expands Leadership Team with the Appointment of Dr. Scott Klakamp as Vice President of Chemistry and Biochemistry 2
... Oct. 21 The U.S. Food and Drug ... been added to the label for the HIV ... effects on the heart when used with Norvir ... http://photos.prnewswire.com/prnh/20090824/FDALOGO ) (Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO ...
... 21 Span-America Medical Systems, Inc. (Nasdaq:  SPAN) will ... conference call on Tuesday, November 2, 2010, covering results ... be released after the regular close of trading the ... conference call will be available online at  www.spanamerica.com ...
Cached Medicine Technology:New Label Changes for Commonly Prescribed HIV Drug Invirase 2
(Date:1/22/2015)... 22, 2015 Padre Murphy's and Owner Tom ... Pro Player Health Alliance (PPHA). The PPHA's passion ... getting everyone, including NFL greats, treated for obstructive sleep apnea ... groups supporting the cause in the valley. The most recent ...
(Date:1/22/2015)... January 22, 2015 Blue Cross and Blue ... who exemplify what it means to “Live Fearless.” ... people to share their stories about how they or someone ... inspired others by living in the moment. By telling these ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 A new ... of experience and person-centeredness in the long-term care environment ... action across the continuum. The paper, “The Power of ... engages perspectives and practices of the patient, resident and ...
(Date:1/22/2015)... January 22, 2015 Carinsurancesavings.biz has released a ... death and dismemberment insurance . , Purchasing an accidental ... be very advantageous. This type of rider provides benefits if ... can be considered a lesser form of life insurance. ...
(Date:1/22/2015)... Weddingshe.com has added many trendy Champagne wedding dresses ... in the past three years. Today, the business announces a ... to the sales manager of the company, this is on ... This point can be reflected on the discounted wedding dresses ...
Breaking Medicine News(10 mins):Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2
... Feb. 20 When Avaya rolls its,18-wheel ... floor of HIMSS08,next week, onboard will be ... are helping healthcare organizations address critical,communications challenges ... a leading global provider of business communications ...
... announced that, due to continuing declines in Portamedic revenues,the ... fourth quarter 2007,excluding the gain on sale of its ... to a greater than expected,reduction in paramedical exams of ... year. Regarding 2008, the Company no longer expects to ...
... MacuSight(TM), Inc., a,developer of innovative therapeutics for ... announced the appointment of Joel Naor,M.D., M.Sc., MBA, ... in the clinical development of therapeutics for ocular ... role in MacuSight,s ongoing,advancement of its sirolimus program, ...
... Feb. 20 IDM Pharma, Inc.,(Nasdaq: IDMI ) ... Market that the Company has regained compliance with NASDAQ,Marketplace ... bid price of at least $1.00 per share., ... Company,s common stock,was $3.14 per share., About IDM ...
... Featured At Premier Las Vegas Training Facility, ... global,leader in dental and aesthetic lasers, today announced ... Dental Studies (LVI), an,internationally recognized leader in post-graduate ... lasers will be utilized at,LVI,s state-of-the-art teaching facility ...
... finds anxiety over financial, preparedness; consumers say health care ... ... WASHINGTON, Feb. 20 American consumers want more from,their health ... care providers and medical records, customized,insurance coverage and wider access to ...
Cached Medicine News:Health News:Avaya Unified Communications Solutions Help Healthcare Organizations Address Multi-Site, Mobile Workforce Challenges 2Health News:Avaya Unified Communications Solutions Help Healthcare Organizations Address Multi-Site, Mobile Workforce Challenges 3Health News:Avaya Unified Communications Solutions Help Healthcare Organizations Address Multi-Site, Mobile Workforce Challenges 4Health News:Hooper Holmes Updates Guidance 2Health News:Hooper Holmes Updates Guidance 3Health News:MacuSight Expands Management Team With Appointment of Dr. Joel Naor as Chief Medical Officer 2Health News:IDM Pharma Announces Compliance With NASDAQ Minimum Bid Price Requirements 2Health News:HOYA ConBio Announces Educational Agreement With LVI Global 2Health News:Groundbreaking Deloitte Survey Reveals Many U.S. Consumers Want Major Changes in Health Care Design, Delivery 2Health News:Groundbreaking Deloitte Survey Reveals Many U.S. Consumers Want Major Changes in Health Care Design, Delivery 3Health News:Groundbreaking Deloitte Survey Reveals Many U.S. Consumers Want Major Changes in Health Care Design, Delivery 4
... These corrosion proof polypropylene exhaust hoods ... edge of tanks and draw a stream ... tank away from the operator. Other sizes ... semi-canopy, lateral, and double-slot are available on ...
These handy dispensers save space and organize gloves in labs and next to hand washers. Static-dissipative PVC eliminates static charges and the particles they attract . Many other sizes and custom c...
... base sliding microtome offers the ultimate in ... not least, safety. ,Designed to meet the ... 8000 will also meet the more demanding ... versatility and wide range of accessories will ...
... Starter Package is a solid ... laboratory. The package includes the ... additional mounting blocks, v-block adapter, ... a rotating stage assembly for ...
Medicine Products: